- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05590429
Blood Transfusion in Patients With Lung Cancer
Frequency and Complications of Blood Transfusion in Patients With Lung Cancer
The main purpose of approaching the anemic patient is to provide and maintain hemoglobin levels that will allow oxygen to reach the tissue at an adequate level. This critical level may vary from patient to patient, the age of the patient and other accompanying diseases are among the determining factors. The most important factor in transfusion indication is the insufficiency of cardiopulmonary compensation mechanisms due to anemia in the patient and the patient becoming symptomatic. Red blood cell (RBC) transfusions are common in the treatment of cancer patients.
In cancer patients, similar to other patient populations, the indication for RBC transfusion is to alleviate anemia, which is actually symptomatic. However, the decision to transfuse should not be guided solely by the hemoglobin concentration.
With this study, it is aimed to develop clinical practices to prevent unnecessary transfusion practices in lung cancer patients, to encourage the application of other supportive treatment options, and to take preventive measures before anemia develops
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Blood is a living tissue composed of specific structures, each with distinct functions. Blood transfusion is a tissue or even organ transplantation. Unnecessary blood transfusion should not be done, and the missing component should be replaced in the patient.
The need for transfusion seen in medical diseases is often in the form of chronic anemia, except for a few conditions that cause sudden bleeding. Repeated transfusions may be required in these patients during the course of their disease and related problems may arise. For this reason, while determining the indication for transfusion, it is absolutely necessary to perform the benefit-harm analysis correctly.
The main purpose of approaching the anemic patient is to provide and maintain hemoglobin levels that will allow oxygen to reach the tissue at an adequate level. This critical level may vary from patient to patient, the age of the patient and other accompanying diseases are among the determining factors. The most important factor in transfusion indication is the insufficiency of cardiopulmonary compensation mechanisms due to anemia in the patient and the patient becoming symptomatic. Red blood cell (RBC) transfusions are common in the treatment of cancer patients.
Generally, patients with oncological and hematological malignancies use approximately 34% of the RBC source. In cancer patients, similar to other patient populations, the indication for RBC transfusion is to alleviate anemia, which is actually symptomatic. However, the decision to transfuse should not be guided solely by the hemoglobin concentration. No single criterion can be used as an indicator of RBC transfusion.
The clinical condition of the patient must be taken into account. Anemia can be seen in approximately 90% of patients during chemotherapy treatment. Cytotoxic drugs often cause the loss, destruction and reduction of RBCs that cause anemia. Especially lung and gynecological cancers are highly associated with anemia. Platinum-based chemotherapeutics are often preferred in the treatment of such cancers. Anemia in cancer can reduce quality of life and increase cancer-related fatigue and may be a poor indicator of clinical outcomes. That is why, in clinical practice, transfusions are often performed in cancer patients.
In general, a hemoglobin level of 7 g / dL is a suitable indicator for red blood cell (RBC) transfusion in stable patients without complications. However, patients with cardiovascular disease or acute coronary syndrome can be transfused at a hemoglobin level of 8 g / dL.
Although the indications for transfusion in patients with other types of complications are unclear, cancer patients have reported improved clinical well-being when kept at about 7 g / dL in hemoglobin levels, but no study results suggested an absolute hemoglobin level that is optimal for patients with cancer.
With this study, it is aimed to develop clinical practices to prevent unnecessary transfusion practices in lung cancer patients, to encourage the application of other supportive treatment options, and to take preventive measures before anemia develops.
Patients who have been followed up and receiving chemotherapy in our chest diseases department in the last 5 years will be included in our study. Patients who were diagnosed with lung cancer between 01/01 / 2014-31 / 12/2018, followed up in the chest diseases service and given chemotherapy will be included in the study. Patient data will be retrospectively collected using file records and hospital automation system (clinical course, blood bank data, consultation records, etc.). The study will begin after the approval of the ethics committee and will continue for 6 months.
Exclusion Criteria; Patients with known hematological malignancies other than lung cancer, patients who were diagnosed with anemia before chemotherapy treatment, who received treatment for this reason, patients who were diagnosed with lung cancer in our clinic but did not continue chemotherapy treatment in our clinic afterwards, and patients who are thought to impair data integrity due to incomplete data will be excluded from the study.
Patients' data to be followed; Exclusion Criteria; Patients with known hematological malignancies other than lung cancer, patients who were diagnosed with anemia before chemotherapy treatment, who received treatment for this reason, patients who were diagnosed with lung cancer in our clinic but did not continue chemotherapy treatment in our clinic afterwards, and patients who are thought to impair data integrity due to incomplete data will be excluded from the study.
Patients' data to be followed; Demographic characteristics, comorbid diseases, cancer type and stage, how long it was followed up with this diagnosis, Hb value before starting chemotherapy, whether RBC transfusion was performed during the follow-up period, which Hb value of blood transfusion was applied, how many units of RBC or other blood were taken during the follow-up period. product replacement, how many cures of chemotherapy they received in total, which chemotherapy drugs they took, whether there was a delay in treatment due to treatment-related anemia, the most frequent indications and complications of transfusion (allergic reaction, febrilereax., infection and thromboembolic complications), whether they received additional radiotherapy. , whether they received GMC-SF due to anemia, blood groups, survival times, how many times there was cancer progression under treatment, and if there is distant metastasis, the location of metastasis was aimed to be screened.
In the analysis of the data; The compliance of the data to normal distribution will be examined by Shapiro Wilk and Kolmogorog Smirnov tests. Kruskall-Wallis, Mann-Whitney U, student-t and chi-square tests will be used for comparisons between groups. General linner modeling, Wilcowon and Friedman tests will be used in serially tracked data. Data will be given as percentage, mean (std deviation) and median (minimum-maximum). The chi-square test will be used to compare qualitative data. Categorical data will be presented in the form of frequency and percentage.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: OLCAY AYCICEK, MD
- Phone Number: 05324409349
- Email: olcayaycicek@yahoo.com
Study Locations
-
-
-
Trabzon, Turkey, 61100
- Recruiting
- Department of Chest Diseases, Division Of Intensive Care Medicine, Faculty of Medicine, Karadeniz Technical University
-
Contact:
- olcay ayçiçek
- Phone Number: 05324409349
- Email: olaycicek75@gmail.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
Patients over 18 years of age diagnosed with non-small cell lung cancer Patients over 18 years of age diagnosed with small cell lung cancer Patients diagnosed with lung cancer and undergoing chemotherapy
Exclusion Criteria:
Patients with known hematological malignancies other than lung cancer, patients who were diagnosed with anemia before chemotherapy treatment, who received treatment for this reason, patients who were diagnosed with lung cancer in our clinic but did not continue chemotherapy treatment in our clinic afterwards, patients who are thought to impair data integrity due to missing data will be excluded from the study
-
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
evaluate the relationship between blood transfusion frequency and disease prognosis
Time Frame: 01.10.2020-01.06.2022
|
With this study, it is aimed to develop clinical practices to prevent unnecessary transfusion practices in lung cancer patients, to encourage the application of other supportive treatment options and to take preventive measures before anemia develops.
|
01.10.2020-01.06.2022
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Mehtap Küçük, MD, Department of Chest Diseases, Division Of Intensive Care Medicine, Faculty of Medicine, Karadeniz Technical University
- Study Chair: A. Oguzhan Küçük, MD, Department of Chest Diseases, Division Of Intensive Care Medicine, Faculty of Medicine, Karadeniz Technical University
- Study Chair: Merve Algın, MD, Department of Chest Diseases, Faculty of Medicine, Karadeniz Technical University
- Study Chair: Ayşegul Pehlivanlar, MD, Department of Chest Diseases, Faculty of Medicine, Karadeniz Technical University
- Study Chair: Funda Öztuna, Prof, Department of Chest Diseases, Faculty of Medicine, Karadeniz Technical University
- Principal Investigator: Olcay Ayçiçek, Department of Chest Diseases, Faculty of Medicine, Karadeniz Technical University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 24237859-782
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Transfusion-Transmitted Infection
-
Johns Hopkins UniversityUnited States Department of Defense; MU-JHU CARE; Terumo BCTRecruitingTransfusion-Transmitted Infectious DiseaseUganda
-
National Institutes of Health Clinical Center (CC)CompletedViral Disease | Blood Donation | Transfusion-Transmitted InfectionsUnited States
-
Cerus CorporationRecruitingAnemiaUnited States, Puerto Rico
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedInfection | Blood Transfusion
-
Mahidol UniversityWolf-Schleinzer-StiftungUnknownInfection After TransfusionThailand
-
Naomi LubanNational Heart, Lung, and Blood Institute (NHLBI)CompletedTransfusion-induced HCV and HGV Infection
-
Aretaieion University HospitalCompletedSurgery | Cytokine Storm | Infection After Transfusion | Transfusion-related Immunomodulation ReactionGreece
-
Wellspect HealthCareCompletedArthroplasty, Replacement, Knee | Blood Transfusion | Blood Transfusion, AutologousPoland
-
Wellspect HealthCareCompletedBlood Transfusion | Arthroplasty, Replacement, Hip | Blood Transfusion, AutologousAustria, Netherlands, Norway, Spain
-
Sunnybrook Health Sciences CentreUniversity Health Network, Toronto; Canadian Blood ServicesCompletedTransfusion-associated Circulatory OverloadCanada
Clinical Trials on Blood transfusion
-
Hamad Medical CorporationSidra Medical and Research Center; World Anti-Doping Agency; Anti-Doping Lab... and other collaboratorsUnknownBlood Disease | Blood Transfusion, Autologous | Blood Doping | Blood Transfusion, HomologousQatar
-
Hospital PitangueirasUnknown
-
Emory UniversityWithdrawnHematopoietic and Lymphoid Cell Neoplasm | Leukemia | Anemia | Myelodysplastic Syndrome | Aplastic Anemia | Bone Marrow FailureUnited States
-
Haukeland University HospitalDentsply Sirona Implants and ConsumablesCompleted
-
Mahidol UniversityWolf Schleinzer Stiftung zur Wissenschafts- und Bildungsförderung, GermanyCompletedSurgery | Immune Defect | Incompatible Blood TransfusionThailand
-
Oregon Health and Science UniversityNot yet recruitingTraumatic Brain Injury
-
Assistance Publique - Hôpitaux de ParisCompletedMyocardial Infarction | Anemia | Blood TransfusionSpain, France
-
Direction Centrale du Service de Santé des ArméesFloralis; TIMC-IMAGRecruitingTrauma | Coagulopathy | Acute HemorrhageFrance
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)TerminatedAcute Myeloid Leukemia | Primary Myelofibrosis | Thrombocytopenia | Acute Lymphoblastic Leukemia | Chronic Lymphocytic Leukemia | Venous Thromboembolism | Myelodysplastic Syndrome | B-Cell Non-Hodgkin Lymphoma | Hematopoietic Cell Transplantation Recipient | Chronic Myelogenous Leukemia, BCR-ABL1 Positive and other conditionsUnited States
-
Assistance Publique - Hôpitaux de ParisInstitut National de la Santé Et de la Recherche Médicale, France; Etablissement... and other collaboratorsRecruitingThe Focus is on the Detection of the Consequences of Autologous Blood Transfusion in Healthy VolunteersFrance